Literature DB >> 629324

Loss of oncogenicity and concomitant increased immunogenicity of murine plasmacytoma cell lines.

G D Sorenson, O S Pettengill, C C Cate.   

Abstract

Murine plasmacytoma cells gradually decrease in oncogenicity with prolonged culture in vitro. Newly established cultures are oncogenic and cause lethal tumors. Subsequently, the cultures are oncogenic but some of the tumors regress. Later in the life of the culture none of the tumors are lethal. The longer the cells are in culture, the less oncogenic they become; eventually the cultures are nononcogenic in normal mice but do cause tumors in irradiated mice. Clones from the cultures vary from being very oncogenic to being nononcogenic. It appears that the nononcogenic cells have a selective growth advantage and become the dominant cell type in the cultures. Nononcogenic cultures are more effective for immunization to subsequent challenge with the original tumor than are the tumor cells or oncogenic cultures and may confer complete protection against lethal tumor challenge in adoptive transfer experiments. Mixtures of nononcogenic and oncogenic cells decrease the tumor-forming ability of the latter when they are injected together in one site or injected separately in two sites.

Entities:  

Mesh:

Year:  1978        PMID: 629324      PMCID: PMC2018238     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  31 in total

1.  LOSS OF NEOPLASTIC PROPERTIES IN VITRO. I. OBSERVATIONS WITH S-180 CELL LINES.

Authors:  G E FOLEY; B P DROLET
Journal:  Cancer Res       Date:  1964-09       Impact factor: 12.701

2.  Reduction of transplantability of Novikoff hepatoma cells grown in vitro and the consequent protecting effect to the host against their malignant progenitor.

Authors:  T C HSU
Journal:  J Natl Cancer Inst       Date:  1960-11       Impact factor: 13.506

3.  Progressions of a reticulum-cell sarcoma of the mouse in vivo and in vitro.

Authors:  C J DAWE; M POTTER; J LEIGHTON
Journal:  J Natl Cancer Inst       Date:  1958-10       Impact factor: 13.506

4.  Studies on culture lines derived from mouse liver parenchymatous cells grown in long-term tissue culture.

Authors:  V J EVANS; N M HAWKINS; B B WESTFALL; W R EARLE
Journal:  Cancer Res       Date:  1958-04       Impact factor: 12.701

5.  Studies on the difference in sarcoma-producing capacity of two lines of mouse cells derived in vitro from one cell.

Authors:  K K SANFORD; R M MERWIN; G L HOBBS; M C FIORAMONTI; W R EARLE
Journal:  J Natl Cancer Inst       Date:  1958-01       Impact factor: 13.506

6.  Further studies in vitro of transplantable mouse lymphosarcoma MB (T 86157).

Authors:  W M DE BRUYN; G O GEY
Journal:  Acta Unio Int Contra Cancrum       Date:  1952

7.  Production of malignancy in vitro. XI. Further results from reinjection of in vitro cell strains into strain C3H mice.

Authors:  W R EARLE; E SHELTON; E L SCHILLING
Journal:  J Natl Cancer Inst       Date:  1950-04       Impact factor: 13.506

8.  Loss and recovery of transplantability of L-P59 cells.

Authors:  M Jurin
Journal:  In Vitro       Date:  1973 Mar-Apr

Review 9.  Malignant transformation of cells in vitro.

Authors:  K K Sanford
Journal:  Int Rev Cytol       Date:  1965

10.  Immunotherapy of cancer with antibody.

Authors:  H S Shin; G R Pasternack; J S Economou; R J Johnson; M L Hayden
Journal:  Science       Date:  1976-10-15       Impact factor: 47.728

View more
  3 in total

Review 1.  Implications of tumor progression on clinical oncology.

Authors:  D R Welch; S P Tomasovic
Journal:  Clin Exp Metastasis       Date:  1985 Jul-Sep       Impact factor: 5.150

2.  Dynamic heterogeneity: experimental metastasis studies with RIF-1 fibrosarcoma.

Authors:  B M Korycka; R P Hill
Journal:  Clin Exp Metastasis       Date:  1989 Jan-Feb       Impact factor: 5.150

3.  Development of highly immunogenic variants of a rat fibrosarcoma line during in vitro cultivation.

Authors:  K Yamashina; T Oikawa; M Kasai; M Naiki; I Chiba; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.